Global Vision

Inaugural artificial intelligence recommendations from NICE on radiotherapy contouring should allow clinicians to spend more time with patients and on complex cases where AI is not an option. But large language models are not appropriate in all cases, cautions Adrian Sutherland, principal healthcare architect at Endava consultancy.

China’s growing market for medtech, estimated at $70bn in 2021, could more than double this decade if the government’s Healthy China 2030 plan stays on track.  

LGBTQ networking group OUTbio has gone from strength to strength since it was founded in 2015, from a small event attended by a handful of executives in Boston to a registered non-profit with affiliated groups across the US alongside international branches.

Jacqueline Henderson was appointed president, Johnson & Johnson Vision, EMEA, in April, as part of a restructuring of senior regional roles. Now overseeing this most culturally diverse of territories for both Vision Care and Surgical Vision, she explains the rationale for the internal realignment and where Johnson & Johnson Vision goes next.

Through an Israeli innovation lab, four big pharma companies are fostering AI-driven start-ups to help solve industry problems.

China, Japan and South Korea are the top economic powerhouses of Asia. They compete not only for production industries such as electronics, but also for medical sciences. China has enormous resources compared with the two other nations.

With strong government support over the past two decades, the Singaporean life sciences industry has matured. Initially known as a manufacturing hub, Singapore’s innovation ecosystem is now thriving, but the challenge is to cultivate commercialization power.

Nuray Yurt, Merck’s business engagement and activation lead for digital data and analytics, told In Vivo about her hopes for the future of AI regulation and how stakeholders ought to reframe their understanding of the sector.

In the Chinese pharmaceutical market, sales of anti-tumor drugs have been showing a steady growth trend in recent years as cancer patient numbers continue to rise.

Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. Brian Yang takes a deeper look into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations. 

Market access deals can make or break routine access to new treatments. So what happens when patient-centricity and deal-making meet? Leela Barham looks at the experience in England.

Astute students of leadership can glean something from every approach. In Vivo asked five Danish biopharma executives to reflect on what characterizes Danish leadership. They shared insights on the defining features of a Danish approach, its pros and cons, and what lessons they can offer leaders from other countries.

For all its good intentions and lauded action toward gender equality, the biotech industry in Scandinavia and the Nordics has a female CEO rate hovering around 23%. While the number of women entering academia, innovative companies and laboratories is healthy, gender equality in the C-suite leaves a lot to be desired. 

As the Kingdom of Saudi Arabia reduces its dependence on oil as an export, one sector it is building up is the life sciences industry. The government is encouraging global companies to manufacture and invest domestically and they are improving their regulatory system and working with local players to enhance access to patients.

Switzerland has enjoyed its neutral status for more than two centuries and with it has built formidable expertise in several industries – including medtech. However, the nation's internal and external dynamics are being threatened by new challenges.

New policy initiatives and “can do” networking openness in Wales are persuading medtech and healthtech innovators to consider the merits of locating in Great Britain’s smallest home nation.